Category: Immunotherapy

Merck Ventures creates new immuno-oncology company iOnctura

Merck, a leading science and technology company, today announced its corporate venture arm Merck Ventures created iOnctura SA, Geneva, Switzerland. This immuno-oncology spin-out company was formed around two assets from the Healthcare R&D portfolio of Merck and three assets from Cancer Research Technology (CRT). http://www.worldpharmanews.com/merckgroup/3986-merck-ventures-creates-new-immuno-oncology-company-ionctura

Roche builds case for T-cell bispecific-anti-PD-L1 combo

Roche has published early clinical data on its bispecific antibody in heavily pretreated patients with metastatic colorectal cancer. The readout hints that the T cell-activating antibody may improve outcomes in this hard-to-treat population when given as a monotherapy and in combination with anti-PD-L1 drug Tecentriq. http://www.fiercebiotech.com/biotech/roche-builds-case-for-t-cell-bispecific-anti-pd-l1-combo

Merck’s Keytruda in combination with chemotherapy gets FDA nod to treat NSCLC

Merck’s Keytruda (pembrolizumab) in combination with pemetrexed (Alimta) and carboplatin (pem/carbo) has been approved by the US Food and Drug Administration (FDA) for the first-line treatment of metastatic nonsquamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression. http://www.pharmaceutical-business-review.com/news/mercks-keytruda-regimen-gets-fda-approval-for-metastatic-nsclc-treatment-110517-5811043